NYSE:CO Global Cord Blood (CO) Stock Price, News & Analysis $1.50 +0.45 (+42.86%) (As of 12/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends About Global Cord Blood Stock (NYSE:CO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Global Cord Blood alerts:Sign Up Key Stats Today's Range$1.00▼$1.5050-Day Range$1.05▼$2.9952-Week Range$2.03▼$5.50Volume14,458 shsAverage Volume216,519 shsMarket Capitalization$182.33 millionP/E Ratio2.34Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGlobal Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.Read More… Receive CO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global Cord Blood and its competitors with MarketBeat's FREE daily newsletter. Email Address CO Stock News HeadlinesAutologous cord-blood-derived cell administration in extremely preterm infantsDecember 16, 2024 | msn.comHazard NJ Traces ‘Forever Chemicals’ From NJ Roots To Global CrisisNovember 24, 2024 | myveronanj.comThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone" December 22, 2024 | Stansberry Research (Ad)U.S. FDA Approves StemCyte Biologics License Application for REGENECYTE™ Cord Blood Cell Therapy ProductNovember 22, 2024 | finance.yahoo.comExtra ingredient to be added to all bread in pregnancy health bidNovember 14, 2024 | msn.comCommon plastic chemical could threaten fertility of humans worldwideNovember 5, 2024 | msn.comWhat’s the Election About? What No One Can Bear to Talk About.November 2, 2024 | msn.comONWARD® Medical Publishes Closing of Bookbuild OfferingOctober 28, 2024 | markets.businessinsider.comSee More Headlines CO Stock Analysis - Frequently Asked Questions How have CO shares performed this year? Global Cord Blood's stock was trading at $1.22 at the beginning of 2024. Since then, CO stock has increased by 23.0% and is now trading at $1.50. View the best growth stocks for 2024 here. How were Global Cord Blood's earnings last quarter? Global Cord Blood Co. (NYSE:CO) posted its earnings results on Tuesday, June, 26th. The medical research company reported $0.04 EPS for the quarter, missing analysts' consensus estimates of $0.13 by $0.09. The medical research company earned $37.14 million during the quarter. How do I buy shares of Global Cord Blood? Shares of CO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Global Cord Blood own? Based on aggregate information from My MarketBeat watchlists, some other companies that Global Cord Blood investors own include Micron Technology (MU), Dynavax Technologies (DVAX), AT&T (T), Vale (VALE), Cisco Systems (CSCO), Pfizer (PFE) and United Microelectronics (UMC). Company Calendar Last Earnings6/26/2018Today12/22/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A Current SymbolNYSE:CO CUSIPN/A CIK1467808 Webwww.globalcordbloodcorp.com Phone(523) 605-8180Fax852-3605-8181Employees1,202Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio2.34 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.24 billion Price / Sales0.15 Cash Flow$0.36 per share Price / Cash Flow4.19 Book Value$6.34 per share Price / Book0.24Miscellaneous Outstanding Shares121,551,000Free FloatN/AMarket Cap$182.33 million OptionableNo Data Beta0.16 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NYSE:CO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global Cord Blood Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Global Cord Blood With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.